Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 3.00 Billion | USD 10.84 Billion | 13.7% | 2024 |
The global heart pump device market size was worth around USD 3.00 Billion in 2024 and is predicted to grow to around USD 10.84 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 13.7% between 2025 and 2034. The report analyzes the global heart pump device market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the heart pump device industry.
Heart failure occurs when the heart is unable to pump enough blood to meet the body's requirements. This syndrome could be caused by coronary artery disease, such as a recent myocardial infarction (heart attack), high blood pressure, atrial fibrillation, valvular heart disease, and other factors. Many different types of heart pump devices are available on the market to assist cardiac circulation, depending on the cardiovascular disease. They are surgically implanted and used to provide temporary or long-term support for heart function in persons who have a weak heart or erratic blood flow. Several people may benefit from heart pump devices as a treatment alternative for mechanical circulatory assistance.
The rise in the prevalence of cardiovascular illnesses, the increase in the elderly population, and the increase in new product advancements by industry participants are all driving the global heart pump device market forward. Due to a scarcity of heart donors, heart pump devices serve as a viable alternative, fueling the global market's expansion. During the projection period, however, constraints such as the high cost of heart pump devices and the poor reimbursement situation in developing countries are projected to limit market growth. Furthermore, the market's growth is hampered by turbulence and high shear stresses associated with mechanical heart valves (MHVs), as well as the need for patients to take constant anti-coagulation therapy.
Long waiting periods for heart transplant procedures to drive global market growth
Due to the rising incidence of CVDs and heart failure in recent years, the demand for heart transplantation has increased dramatically. However, a global shortage of suitable hearts for transplantation has developed from the inability to meet current demand. As of March 2018, there were around 3,980 candidates on the heart transplant waiting list, according to the national database kept by the Health Resources and Services Administration (US). Significant disparities in the number of donors and patients on waiting lists have been seen even at the country level. In Australia, for example, around 1,650 people were on the waiting list for a heart transplant in 2020, but only 463 donors were available (Source: Transplant Australia Ltd).According to the Transplant Activity Report 2018/19, the number of patients on heart transplant waiting lists had climbed by 134% since 2010. In this situation, not only has the number of patients on the transplant waiting list increased, but so has the number of patients who have died while on the waiting list.
As a bridge-to-transplantation (BTT) or destination therapy for advanced HF, LVADs have become crucial tools (DT). The expanding number of end-stage HF patients, combined with technological advancements in mechanical circulatory support (MCS), has raised demand for MCS devices used in these patients. Between 2009 and 2016, MCS, LVAD, RVAD, TAH, and ECMO were used to bridge 43 percent of beneficiaries. These devices give patients with the required support while they wait for a heart transplant or as a long-term option for those who are not candidates for a heart transplant. As a result of the considerable gap between demand and supply of donor hearts, the heart pump devices market is likely to rise in the future years.
High cost of heart pump device equipment in Heart Pump Devices to hamper the market growth
For bridge-to-heart transplantation, ventricular support devices, notably left ventricular assist devices (LVADs), are commonly employed. Although LVADs are considered life-saving devices, they do come with a number of drawbacks. By six months after implantation, up to 60% of patients have experienced LVAD-related problems. Nearly 80% of patients had at least one adverse event after two years. Readmissions to the hospital that were not scheduled are common. Patients are readmitted on average 2.2 times over the course of their 11-month median follow-up period. Device thrombosis, bleeding issues, renal impairment, ischemic and hemorrhagic strokes, multi-organ failure, and infections are all major non-surgical adverse events and consequences linked with LVAD. If left untreated, certain problems can be fatal to the victims.
Development of non-invasive, portable, and advanced fetal monitors to bring growth opportunities for global market
Various companies with items in the development phase make up the devices market. Companies with products in the pipeline concentrate on finding unique solutions that will help the market grow faster. For example, the TAH industry is a fast-paced area of device development that is expected to have a rise in launches and approvals in the future years. When compared to the SynCardia Total Heart (sole player until December 2020), these TAHs offer more sophisticated functions, making them a better alternative in the future. CARMAT's entire artificial heart, for example, got the CE Mark in December 2020. CARMAT's TAH is self-regulating, changing blood flow in response to the patient's physical activity.
Report Attributes | Report Details |
---|---|
Report Name | Heart Pump Device Market |
Market Size in 2024 | USD 3.00 Billion |
Market Forecast in 2034 | USD 10.84 Billion |
Growth Rate | CAGR of 13.7% |
Number of Pages | 110 |
Key Companies Covered | Abbott Laboratories (US), Abiomed (US), Medtronic (Ireland), Teleflex Incorporated (US), SynCardia Systems (US), Fresenius Medical Care AG & Co. KGaA (Germany), Getinge (Sweden), CardiacAssist Inc (US), Berlin Heart (Germany), Jarvik Heart Inc (US), CARMA, and others. |
Segments Covered | By Product, By Type, By Therapy, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
The global Heart Pump Device market is segregated based on product ,type,therapy and region.
The heart pump devices market is divided into three categories based on products: ventricular assist devices, intra-aortic balloon pumps, and whole artificial hearts. The largest and fastest-growing segment of this market is ventricular assist devices. Technological developments, a scarcity of organ donors, and an increase in the global prevalence of heart failure are all contributing to this segment's growth.
The market is divided into implanted heart pump devices and extracorporeal heart pump devices based on type. Due to the introduction of innovative products by major players and the increased need for an efficient solution to manage heart failure, implantable heart pump devices will account for the highest share of this market by 2020.
The market is divided into bridge-to-transplant (BTT), bridge-to-candidacy (BTC), destination treatment (DT), and other therapies, depending on the therapy. The BTT segment held the greatest proportion of this market in 2020. The rise is the segment is due to the availability of VADs for BTT and increased awareness of transplantation
The market for heart pump devices is dominated by the Americas, owing to an increase in the frequency of cardiovascular disorders and an ageing population. Moreover, the government's increased initiatives, as well as funding for research & development in innovative medical treatment alternatives, will fuel the expansion of the heart pump devices market in the region throughout the forecast period. Due to an increase in the frequency of chronic cardiovascular illnesses and rising healthcare costs, Asia-Pacific is expected to see considerable growth in the heart pump devices market. Furthermore, the region's improving standard of living is expected to fuel the expansion of the heart pump devices market in the future years.
Some of the main competitors dominating the global Heart Pump Device market include -
By Product
By Type
By Therapy
By Region
FrequentlyAsked Questions
The global heart pump device market is expected to grow due to rising prevalence of cardiovascular diseases, growing adoption of minimally invasive procedures, and advancements in device technology.
According to a study, the global heart pump device market size was worth around USD 3.00 Billion in 2024 and is expected to reach USD 10.84 Billion by 2034.
The global heart pump device market is expected to grow at a CAGR of 13.7% during the forecast period.
North America is expected to dominate the heart pump device market over the forecast period.
Leading players in the global heart pump device market include Abbott Laboratories (US), Abiomed (US), Medtronic (Ireland), Teleflex Incorporated (US), SynCardia Systems (US), Fresenius Medical Care AG & Co. KGaA (Germany), Getinge (Sweden), CardiacAssist Inc (US), Berlin Heart (Germany), Jarvik Heart Inc (US), CARMA, among others.
The report explores crucial aspects of the heart pump device market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed